Part:BBa_K1011001:Design

P + RBS + ftsZ + RBS + GFP + Term

Assembly Compatibility:

• 10
  COMPATIBLE WITH RFC[10]
• 12
  COMPATIBLE WITH RFC[12]
• 21
  COMPATIBLE WITH RFC[21]
• 23
  COMPATIBLE WITH RFC[23]
• 25
  INCOMPATIBLE WITH RFC[25]

  Illegal AgeI site found at 403
  
• 1000
  INCOMPATIBLE WITH RFC[1000]

  Illegal BsaI.rc site found at 1903
  

Design Notes

none

Source

The biobricks are all previous submissions. The novel part of this biobrick is the ftsZ gene, biobrick K1011000.

References

The European CanCer Organisation (ECCO). (2012, November 7). First trial in humans of 'minicells': A completely new way of delivering anti-cancer drugs. Science Daily, Retrieved from http://www.sciencedaily.com/releases/2012/11/121108181443.htm

Flemming, A. (2007). Minicells deliver lethal load to tumours. Nature Reviews Drug Discovery, 6, 519. doi: 10.1038/nrd2366.

Giacalone, M. J. et al. (2007). Immunization with non-replicating e. coli minicells delivering both protein antigen and dna protects mice from lethal challenge with lymphocytic choriomeningitis virus. Vaccine,25(12), 2279-2287. doi: 10.1016/j.vaccine.2006.11.069.

MacDiarmid, J. A., & Brahmbhatt, H. (2011). Minicells: Versatile vectors for targeted drug or si/shrna cancer therapy. Current Opinion in Biotechnology, 22, 909-916. doi: 10.1016/j.copbio.2011.04.008

MacDiarmid, J. A. et al. (2009). Sequential treatment of drug-resistant tumors with targetedminicells containing sirna or a cytotoxic drug. Nature Biotechnology,27(7), 643-654. doi: 10.1038/nbt.1547.

MacDiarmid, J. A. et al. (2007). Bacterial derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell, 11, 431-445. doi: 10.1016/j.ccr.2007.03.012.

Ward, J. E., & Lutkenhaus, J. (1985). Overproduction of ftsz induces minicell formation in e. coli. Cell, 42, 941-949. doi: 10.1016/0092-8674(85)90290-9.